On March 11, 2022, Novan, Inc. (Nasdaq: NOVN), announced its acquisition of EPI Health, LLC, a specialty pharmaceutical company focused on the U.S. dermatology market. Novan management hosted a conference call and webcast presentation for investors, analysts, and other interested parties to discuss the acquisition on March 11, 2022. The webcast has been archived for 90 days on the Events page of the Investors section of the Novan website. “As we prepare for the planned NDA submission of our lead product candidate, SB206 (berdazimer gel 10.3%), it was imperative that we evaluate a broad spectrum of options for potential commercialization. This acquisition creates a robust commercial infrastructure for Novan, and I believe sets the stage for the future success of the company. As of today, we have launched Novan as a fully-integrated specialty dermatology company with a solid pipeline of development candidates complemented by a commercial foundation to further position Novan to realize the value of each,” commented Paula Brown Stafford (photo), MPH, Chairman and Chief Executive Officer of Novan. “I am thoroughly excited about the synergies this transaction offers as it has the potential to propel Novan into a leading global dermatology company. I am pleased to welcome EPI Health to the Novan family.”